Suppose we want to investigate the effectiveness of two potential COVID-19 vaccines. We will call these "Vaccine 1" and "Vaccine 2".
During Phase 3 trials of the vaccine development process, thousands of volunteers are randomly assigned one of the two vaccines. After 30 days, researchers take blood samples to detect if antibodies are present. The presence of antibodies would indicate that the vaccine has been effective at preventing the individual from experiencing moderate to severe COVID-19 symptoms. The table below shows the results of some randomly selected volunteers from each vaccine trial.
| |
Antibodies present |
No antibodies present |
| Vaccine 1 |
53 |
22 |
| Vaccine 2 |
59 |
16 |